The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

A new head-to-head study reveals tirzepatide achieves 47% more weight loss than semaglutide in people with obesity but without diabetes, highlighting its superior effectiveness and cardiometabolic ...

Over the past few years, a new class of injectable medications has changed the way obesity is treated. Two drugs—tirzepatide ...

Roll out of weight loss drugs in England could be dramatically sped up to millions of working age adults by making use of ...

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

Injectable drugs like Ozempic and Mounjaro have transformed obesity treatment by mimicking gut hormones. But experts have ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Online weight loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy ...

Tirzepatide discontinuation was associated with reduced cardiometabolic benefits especially among patients with body weight ...

In the first direct comparison study involving individuals with obesity, tirzepatide demonstrated approximately 50% greater ...

Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.

The suit comes amid recent studies showing a link between vision complications and people taking drugs containing semaglutide ...